The Incidence, Mortality, and Survival of Breast Cancer per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis
Author(s)
Vlad Zah, DPhil, Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c).
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Surveillance, Epidemiology, and End Results (SEER; released April 2025) data were used to investigate the breast cancer (BC) burden in the US.
METHODS: 17 cancer registries (January 2018 - December 2022) were analyzed with SEER*Stat. BC patients were the target population. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival.
RESULTS: 377,387 BC patients were captured. The most common were HER2-/HR+ subtypes (59.49%) and localized stage (53.51%). Patients were mostly 20-64 years old (55.23%), females (99.21%), non-Hispanic Whites (62.29%), married (55.21%), metropolitan county residents (90.38%), and had $65,000-90,000 annual household income (AHI) (43.93%). The BC incidence was 86.24/100,000. The most common was localized HER2-/HR+ BC (34.99/100,000). Across demographic groups, the rates were higher in the elderly (251.50/100,000), females (170.06/100,000), non-Hispanic Whites (106.56/100,000), non-metropolitan area residents (86.96/100,000), and >$120,000 AHI (94.26/100,000). Incidence increased from 2018 (85.05/100,000) to 2022 (90.05/100,000), with a slight decline in 2020 (77.95/100,000). The BC mortality was 37.58/100,000. The highest rates per group were reported for localized HER2-/HR+ BC (6.99/100,000), elderly (199.58/100,000), females (73.87/100,000), non-Hispanic Whites (53.12/100,000), non-metropolitan area residents (48.68/100,000), and <$40,000 AHI (53.48/100,000). Mortality consistently increased from 2018 (34.03/100,000) to 2022 (41.92/100,000). In 2018, the 4-year survival rate was 88.58%. However, distant BC had a much lower rate (37.05%), especially if HER2-/HR+ status was undetermined (10.70%) or the HER2-/HR- subtype was diagnosed (15.15%). Among demographic groups, the lowest 4-year rates were reported for males (80.77%), non-Hispanic Blacks (83.00%), and non-metropolitan county residents (85.08%). The 1-year rates between 2018 (96.86%) and 2021 (96.57%) were similar. The lowest 1-year survival in 2021 was observed for distant BC (69.38%), especially for those with undetermined HER2/HR status (29.49%).
CONCLUSIONS: This study may indicate high BC burden in the US. Incidence and mortality rates are high and increasing each year, while the survival of specific subtypes/stages remains low.
METHODS: 17 cancer registries (January 2018 - December 2022) were analyzed with SEER*Stat. BC patients were the target population. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival.
RESULTS: 377,387 BC patients were captured. The most common were HER2-/HR+ subtypes (59.49%) and localized stage (53.51%). Patients were mostly 20-64 years old (55.23%), females (99.21%), non-Hispanic Whites (62.29%), married (55.21%), metropolitan county residents (90.38%), and had $65,000-90,000 annual household income (AHI) (43.93%). The BC incidence was 86.24/100,000. The most common was localized HER2-/HR+ BC (34.99/100,000). Across demographic groups, the rates were higher in the elderly (251.50/100,000), females (170.06/100,000), non-Hispanic Whites (106.56/100,000), non-metropolitan area residents (86.96/100,000), and >$120,000 AHI (94.26/100,000). Incidence increased from 2018 (85.05/100,000) to 2022 (90.05/100,000), with a slight decline in 2020 (77.95/100,000). The BC mortality was 37.58/100,000. The highest rates per group were reported for localized HER2-/HR+ BC (6.99/100,000), elderly (199.58/100,000), females (73.87/100,000), non-Hispanic Whites (53.12/100,000), non-metropolitan area residents (48.68/100,000), and <$40,000 AHI (53.48/100,000). Mortality consistently increased from 2018 (34.03/100,000) to 2022 (41.92/100,000). In 2018, the 4-year survival rate was 88.58%. However, distant BC had a much lower rate (37.05%), especially if HER2-/HR+ status was undetermined (10.70%) or the HER2-/HR- subtype was diagnosed (15.15%). Among demographic groups, the lowest 4-year rates were reported for males (80.77%), non-Hispanic Blacks (83.00%), and non-metropolitan county residents (85.08%). The 1-year rates between 2018 (96.86%) and 2021 (96.57%) were similar. The lowest 1-year survival in 2021 was observed for distant BC (69.38%), especially for those with undetermined HER2/HR status (29.49%).
CONCLUSIONS: This study may indicate high BC burden in the US. Incidence and mortality rates are high and increasing each year, while the survival of specific subtypes/stages remains low.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH244
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology